Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Details)

v3.8.0.1
Significant Accounting Policies (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2017
USD ($)
Mar. 31, 2018
USD ($)
product
Mar. 31, 2017
USD ($)
Sep. 30, 2013
USD ($)
Dec. 31, 2017
USD ($)
segment
class_of_stock
Dec. 31, 2016
USD ($)
class_of_stock
SIGNIFICANT ACCOUNTING POLICIES            
Reclassification adjustment   $ 317,287        
Accounts receivable, net   2,830,354     $ 2,935,025  
Escrowed Cash Receivable [Abstract]            
Proceeds on sale of rights $ 25,000,000          
Escrowed cash receivable $ 3,750,000 3,754,455     3,752,390  
Escrow period 12 months          
Reserve on escrow receivable   0        
Restricted Cash            
Restricted Cash   $ 145,314 $ 83,037   $ 133,312  
Deposits           $ 50,000
Security deposit required, end of third year       $ 13,000    
Concentration Risk            
Number of product lines | product   6        
Clinical Trial Expense Accruals            
Number of material adjustments to prior period estimates of accrued expenses | class_of_stock         0 0
Segment Reporting Information, Additional Information [Abstract]            
Number of operating segments | segment         1  
Employee Stock Purchase Plan (ESPP)            
Restricted Cash            
Restricted Cash   $ 14,000        
Sales Revenue | Customer Concentration Risk | Major Customer Number One            
Concentration Risk            
Concentration risk percentage   22.00%        
Sales Revenue | Customer Concentration Risk | Major Customer Number Two            
Concentration Risk            
Concentration risk percentage   25.00%        
Sales Revenue | Customer Concentration Risk | Major Customer Number Three            
Concentration Risk            
Concentration risk percentage   29.00%        
Sales Revenue | Product Concentration Risk            
Concentration Risk            
Concentration risk percentage   100.00%        
Accounts Payable | Vendor Concentration Risk            
Concentration Risk            
Concentration risk percentage   51.00% 57.00%      
Minimum            
Distribution Fees and Rebates            
Medicaid billing period   180 days        
Maximum            
Returns and Allowances            
Product return period prior to expiration   6 months        
Product return period after expiration   1 year        
Distribution Fees and Rebates            
Medicaid billing period   270 days